Patents Assigned to Nihon Medi-Physics Co., Ltd.
  • Publication number: 20170362226
    Abstract: The present invention relates to a radioactive halogen-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a specific general formula or a salt thereof, or a radiopharmaceutical comprising the same.
    Type: Application
    Filed: February 24, 2016
    Publication date: December 21, 2017
    Applicants: KYOTO UNIVERSITY, NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Masahiro ONO, Hideo SAJI, Masafumi IHARA, Hiroki MATSUMOTO, Ikuya SEKI
  • Publication number: 20170281803
    Abstract: The present invention provides a renal imaging agent comprising a nitroimidazole-type compound or a salt thereof. The renal imaging agent according to the present invention can be used in positron emission tomography.
    Type: Application
    Filed: September 7, 2015
    Publication date: October 5, 2017
    Applicant: NIHON MEDI-PHYSICS CO., LTD.
    Inventor: Norihito NAKATA
  • Publication number: 20170265441
    Abstract: Provided is a method for producing an animal model of osteoblastic bone metastasis. A non-human animal in which an osteoblastic lesion is formed in a wide range has been successfully produced with a probability of 100% by: administering a calcineurin inhibitor to a non-human animal; and injecting a tumor cell into an artery or a vein of the non-human animal, wherein the non-human animal and the tumor cell are in an allogeneic or xenogeneic relation.
    Type: Application
    Filed: February 28, 2017
    Publication date: September 21, 2017
    Applicant: NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Shuntaro OKA, Masaru KANAGAWA, Masahiro ONO, Yoshihiro DOI
  • Publication number: 20170251547
    Abstract: Disclosed is a target device (10) having a plurality of target material plates (20a, 20b) for producing a radionuclide, lined up in an overlapped manner, configured to produce the radionuclide when a particle beam is irradiated on the target material plates (20a, 20b), the target device (10) having a front plate group (GRF) composed of target material plates (20a) positioned to the front side the particle beam comes in, and a rear plate group (GRR) composed of the target material plates (20b) positioned to the rear side, and the average thickness of the target material plates (20a) composing the front plate group (GRF) being smaller than the average thickness of the target material plates (20b) composing the rear plate group (GRR).
    Type: Application
    Filed: February 20, 2017
    Publication date: August 31, 2017
    Applicant: Nihon Medi-Physics Co., Ltd.
    Inventor: Taku ITO
  • Publication number: 20170231591
    Abstract: To provide a technique for evaluating a nuclear medicine brain image, the technique being hardly affected by the difference in the setting of reference regions. An embodiment of the present invention generally includes: setting a reference region on a region corresponding to the scalp in the nuclear medicine brain image; calculating information on a pixel value in the set reference region; and normalizing, using the information, a pixel value of each pixel included in the nuclear medicine brain image or a value obtained from the pixel value, and outputting the normalized value.
    Type: Application
    Filed: October 29, 2015
    Publication date: August 17, 2017
    Applicant: Nihon Medi-Physics Co., Ltd.
    Inventors: Akihiro MURATA, Shigenori MORISHITA, Yoshihiro DOI, Ryohei KOBAYASHI
  • Publication number: 20170158668
    Abstract: Provided is a compound represented by general formula (1) or a salt thereof as well as a medicine containing the compound or the salt. In the formula, R1, R2, R3, R4, R5, X1, X2, and X3 are defined.
    Type: Application
    Filed: June 25, 2015
    Publication date: June 8, 2017
    Applicants: Nihon Medi-Physics Co., Ltd., Kyoto University, National Hospital Organization
    Inventors: Akihiro IZAWA, Kei AKAMA, Yuki OKUMURA, Yurie FUKUI, Nobuya KOBASHI, Tsutomu ABE, Yoshihiro DOI, Miho IKENAGA, Hideo SAJI, Hiroyuki KIMURA, Mitsuhide NARUSE
  • Publication number: 20170066748
    Abstract: There is provided a labeling precursor compound represented by the following general formula (2): wherein R1 represents an alkynyl group, an alkynyloxy group, an azide group, an azidoalkyl group, an arylazide group, a monocyclic or condensed polycyclic aryl group or a nitrogen-containing heterocycle; R2 and R3 each independently represent an alkyl group or a hydroxyalkyl group which hydroxy group may be protected with a protecting group, and n is an integer of 1 or 2; R6 represents an alkyl group or —CONR11R12 wherein R11 and R12 each independently represent an alkyl group or a monocyclic or condensed polycyclic aryl group; and R4, R5, R7 and R8 each independently represent a hydrogen atom, an alkyl group or an alkoxy group.
    Type: Application
    Filed: September 1, 2016
    Publication date: March 9, 2017
    Applicants: NIHON MEDI-PHYSICS CO., LTD., TOKYO INSTITUTE OF TECHNOLOGY
    Inventors: Masahito TOYAMA, Masato KIRIU, Hiroshi TANAKA
  • Patent number: 9424642
    Abstract: One of the preferred embodiments includes: (a) creating a summed 3D nuclear medicine imaging data by summing a plurality of 3D nuclear medicine imaging data pixel by pixel; (b) determining pixels corresponding to myocardial regions in the summed 3D nuclear medicine imaging data; (c) defining a plurality of tracing directions based on the summed 3D nuclear medicine imaging data, and determining a reference myocardial center base point, a reference inner myocardial wall base point and a reference outer myocardial wall base point for each of the tracing directions; (d) determining a phase-specific myocardial center base point for each of the tracing directions for each of the phases; and (e) seeking a difference between the reference myocardial center base point and the phase-specific myocardial center base point, and determining a phase-specific inner myocardial wall base point and a phase-specific outer myocardial wall base point.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: August 23, 2016
    Assignee: Nihon Medi-Physics Co., Ltd.
    Inventors: Kazuo Hamada, Kazunori Kobayashi
  • Patent number: 9387266
    Abstract: It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by —OR2; R2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R3 is a protective group.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: July 12, 2016
    Assignee: NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Osamu Ito, Akio Hayashi, Fumie Kurosaki, Masahito Toyama, Toshiyuki Shinmura, Arinori Harano
  • Patent number: 9381259
    Abstract: It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by —OR2; R2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R3 is a protective group.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: July 5, 2016
    Assignee: NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Osamu Ito, Akio Hayashi, Fumie Kurosaki, Masahito Toyama, Toshiyuki Shinmura, Arinori Harano
  • Patent number: 9211350
    Abstract: A compound represented by the following formula (1), or a salt thereof: wherein R1 is a radioactive halogen substituent, 0 to 2 of A1, A2, A3 and A4 represent N, and the rest represent —(CH)— is effective as a diagnostic imaging probe targeting amyloid. A diagnostic agent for Alzheimer's disease contains a compound represented by the above formula (1) or a salt thereof. After administration to a patient, the compound and the diagnostic agent for Alzheimer's disease transfer into the patient's brain, and indicate good accumulation on amyloid deposited in the brain.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: December 15, 2015
    Assignee: NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Yuki Okumura, Yoshifumi Maya, Yoshinari Shoyama, Takako Onishi
  • Patent number: 9202293
    Abstract: Contour information is extracted from nuclear medicine projection data on a subject not subjected to a scattering correction and an absorption correction by performing a pixel value binarization processing based on a threshold scheme. If necessary, an interpolation processing is performed before reconstructing an image through an image reconstruction processing. Based on the reconstructed image, a second binarization processing is performed to generate a contour image.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: December 1, 2015
    Assignees: Nihon Medi-Physics Co., Ltd., National Cerebral and Cardiovascular Center
    Inventors: Hidehiro Iida, Mayumi Nakazawa
  • Patent number: 9149546
    Abstract: A compound that is effective as a diagnostic imaging probe that targets amyloid including is represented by the following formula (1), or salt thereof: wherein R1 is a radioactive halogen substituent, A1 and A2 independently represent CH or N. A diagnostic agent for Alzheimer's disease includes the compound represented by the above formula or a salt thereof. The above compound and the above diagnostic agent for Alzheimer's disease transfer into brain after administration, and indicate good accumulation on amyloid deposited in the brain.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: October 6, 2015
    Assignee: NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Yuki Okumura, Yoshifumi Maya, Yoshinari Shoyama, Takako Onishi
  • Patent number: 9129373
    Abstract: A measuring image acquisition means 2 acquires a 3-D measuring image in which a phantom filled with the radioactive material into a necessary part is measured with a SPECT system. A measuring image Fourier transform means 4 operates the 3-D measuring image with the 3-D Fourier transform. An actual image acquisition means 6 acquires a 3-D actual image of the part of the phantom which is filled with the radioactive material. An actual image Fourier transform means 8 operates a 3-D actual image with the 3-D Fourier transform. An error image calculation means 10 divides each Fourier transform value of the 3-D Fourier transform measuring image by each Fourier transform value of the corresponding 3-D Fourier transform actual image and acquires a 3-D Fourier transform error image. A point spread function calculation means 12 operates the 3-D Fourier transform error image with the inverse Fourier transform and determines the point spread function image by calculation.
    Type: Grant
    Filed: September 25, 2012
    Date of Patent: September 8, 2015
    Assignees: NIHON MEDI-PHYSICS CO., LTD., NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
    Inventors: Hidehiro Iida, Tsutomu Zeniya, Yuki Hori, Mayumi Nakazawa
  • Patent number: 9107964
    Abstract: The present invention is a compound represented by the following formula (1) or a salt thereof. In the formula (1), R1 denotes a hydrogen atom, a methyl group, or a hydroxymethyl group, and n is an integer of 1 or 2.
    Type: Grant
    Filed: September 18, 2012
    Date of Patent: August 18, 2015
    Assignees: NIHON MEDI-PHYSICS CO., LTD., NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Norihito Nakata, Yuki Okumura, Masato Kiriu, Eriko Nagata, Hiroki Matsumoto, Yuji Kuge, Songji Zhao, Ken-Ichi Nishijima
  • Patent number: 9044520
    Abstract: Embodiments of the invention provide a compound accumulating in an inflammatory site, a diagnostic agent containing the compound in labeled state and its precursor compound for labeling. Such a compound accumulating in inflammatory site may be represented by the following formula (1): Z—Y-Leu-Phe-(X)n-DLys(-(DLys)m-HalB)-(DLys)k-NH2??(1) wherein in the formula (1), Z represents a protective group for an amino group; Y represents Met or Nle; X represents a spacer consisting of one or more of amino acid and/or synthetic organic compounds; n represents 1 or 0; m represents 1 or 0; k represents 1 or 0; and HalB represents a substituted benzoic acid having a radioactive halogen in an aromatic ring.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: June 2, 2015
    Assignees: Nihon Medi-Physics Co., Ltd., Kyoto University
    Inventors: Hideo Saji, Hiroyuki Kimura, Masahiro Ono, Ikuya Seki
  • Publication number: 20140213817
    Abstract: It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by —OR2; R2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R3 is a protective group.
    Type: Application
    Filed: April 7, 2014
    Publication date: July 31, 2014
    Applicant: Nihon-Medi-Physics Co., Ltd.
    Inventors: Osamu ITO, Akio Hayashi, Fumie Kurosaki, Masahito Toyama, Toshiyuki Shinmura, Arinori Harano
  • Patent number: 8790620
    Abstract: A composition including a radioactive fluorine-labeled amino acid compound is provided, which can be prevented from radiolysis. Disclosed is a composition which includes a solution containing a radioactive fluorine-labeled amino acid compound as an effective ingredient, in which the pH value of the solution is kept at 2.0-5.9, more preferably 2.0-4.9 in order to inhibit radiolysis. Also, it is possible to further inhibit radiolysis by adding thereto a pharmaceutical additive capable of inhibiting radiolysis, such as a sugar, a sugar alcohol and a sugar lactone, while the pH is kept at 2.0-5.9.
    Type: Grant
    Filed: November 20, 2007
    Date of Patent: July 29, 2014
    Assignee: Nihon Medi-Physics Co., Ltd.
    Inventors: Akio Hayashi, Toshiyuki Shinmura, Daisaku Nakamura, Soichi Takasaki, Shinji Tokunaga, Emi Kaneko, Masahito Toyama
  • Publication number: 20140186260
    Abstract: A radiopharmaceutical comprising combination of a particular radioactive dithiosemicarbazone copper complex, and a chelating agent comprising a multidentate ligand having a maximum dentate number of 2 or more to 4 or less.
    Type: Application
    Filed: December 24, 2013
    Publication date: July 3, 2014
    Applicants: NIHON MEDI-PHYSICS CO., LTD., NATIONAL CANCER CENTER, NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES
    Inventors: Yukie YOSHII, Hiroki Matsumoto, Mitsuyoshi Yoshimoto
  • Publication number: 20140187784
    Abstract: It is intended to provide a radioactive compound that has higher selectivity for CYP11B2 than that for CYP11B1, exhibits highly selective accumulation in the adrenal gland compared with blood and organs adjacent to the adrenal gland, and permits commercial supply. The present invention provides a radioactive quinolinone derivative represented by the predetermined general formula or a salt thereof.
    Type: Application
    Filed: December 19, 2013
    Publication date: July 3, 2014
    Applicants: Nihon Medi-Physics Co., Ltd., Kyoto University
    Inventors: Hideo Saji, Hiroyuki Kimura, Masahiro Ono, Hiroki Matsumoto